Evidence map›Paper›PMID 32293871›Full record

ArticleACS chemical biology2020

Substrate Recognition by the Class II Lanthipeptide Synthetase HalM2.

Imran R Rahman, Jeella Z Acedo, Xiaoran Roger Liu, Lingyang Zhu, Justine Arrington, Michael L Gross, Wilfred A van der Donk

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Leveraging latent space models for enzyme discovery and sampling.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Promiscuity of lanthipeptide enzymes: new challenges and applications.World journal of microbiology & biotechnology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. A peptide dehydratase with core strength.Nature chemical biology · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. The structure of MadC fromFrontiers in microbiology · 2022
    Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Imran R RahmanDepartment of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0001-9195-0164
Jeella Z AcedoDepartment of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0002-6648-770X
Xiaoran Roger LiuDepartment of Chemistry, Washington University in St. Louis, St. Louis, Missouri 63130, United States.ORCID 0000-0003-3198-1588
Lingyang ZhuSchool of Chemical Sciences NMR Laboratory, Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0002-6657-271X
Justine ArringtonRoy J. Carver Biotechnology Center, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0003-1511-8805
Michael L GrossDepartment of Chemistry, Washington University in St. Louis, St. Louis, Missouri 63130, United States.ORCID 0000-0003-1159-4636
Wilfred A van der DonkDepartment of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0002-5467-7071
University of Illinois Urbana-Champaign · USHoward Hughes Medical Institute · USWashington University in St. Louis · US

Funding

TrainingP41GM103422 · NIGMS · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2012 to 2019
$12.0M
Training Program in Chemistry-Interface with BiologyT32GM070421 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI HERGENROTHER, PAUL · 2005 to 2019
$5.4M
Training Program at the Chemistry Biology InterfaceT32GM136629 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Paul Hergenrother · 2020 to 2026
$4.5M
Posttranslational Modifications in Natural Product BiosynthesisR01GM058822 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI VAN DER DONK, WILFRED A. · 1999 to 2015
$3.8M
Posttranslational Modifications during Natural Product BiosynthesisR37GM058822 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI VAN DER DONK, WILFRED A. · 2016 to 2025
$2.9M
NIGMS NIH HHS P41 GM103422NIGMS NIH HHS R01 GM058822NIGMS NIH HHS R37 GM058822NIGMS NIH HHS T32 GM070421NIGMS NIH HHS T32 GM136629
6 · The paper itself

Abstract

Class II lanthipeptides belong to a diverse group of natural products known as ribosomally synthesized and post-translationally modified peptides (RiPPs). Most RiPP precursor peptides contain an N-terminal recognition sequence known as the leader peptide, which is typically recognized by biosynthetic enzymes that catalyze modifications on the C-terminal core peptide. For class II lanthipeptides, these are carried out by a bifunctional lanthipeptide synthetase (LanM) that catalyzes dehydration and cyclization reactions on peptidic substrates to generate thioether-containing, macrocyclic molecules. Some lanthipeptide synthetases are extraordinarily substrate tolerant, making them promising candidates for biotechnological applications such as combinatorial biosynthesis and cyclic peptide library construction. In this study, we characterized the mode of leader peptide recognition by HalM2, the lanthipeptide synthetase responsible for the production of the antimicrobial peptide haloduracin β. Using NMR spectroscopic techniques,

Indexed as

Amino Acid SequenceCyclizationNuclear Magnetic Resonance, BiomolecularPeptide SynthasesProtein Processing, Post-TranslationalSubstrate SpecificityPeptide Synthases

Identifiers

PMID32293871
PMCPMC7305956
OpenAlexW3015276216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.